Last reviewed · How we verify
Gastromark (FERUMOXSIL)
Gastromark (generic name: FERUMOXSIL) is a drug developed by Amag Pharms Inc. It is currently FDA-approved (first approved 1996) for Magnetic resonance imaging.
There is limited information available on Gastromark, and its modality is unknown. It is also known by the synonyms AMI-121 and Ferumoxsil.
At a glance
| Generic name | FERUMOXSIL |
|---|---|
| Sponsor | Amag Pharms Inc |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
- Magnetic resonance imaging
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gastromark CI brief — competitive landscape report
- Gastromark updates RSS · CI watch RSS
- Amag Pharms Inc portfolio CI
Frequently asked questions about Gastromark
What is Gastromark?
What is Gastromark used for?
Who makes Gastromark?
What is the generic name of Gastromark?
When was Gastromark approved?
What development phase is Gastromark in?
Related
- Manufacturer: Amag Pharms Inc — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Magnetic resonance imaging
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing